Self-medication industry calls to be let off Class III hook and pharma rules for combinations
This article was originally published in Clinica
Executive Summary
The European Commission's proposed new EU regulation on medical devices is too dogmatic when it comes to the classification of drug/device combination products that are manufactured by the self-medication industry and used by consumers, and considered generally “low-risk”.
You may also be interested in...
EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency
Notified bodies have been a pivotal part of the EU medtech regulatory system since it was first launched in the 1990s. Where might they fit within a new medtech regulatory governance structure? Panelists on a recent vodcast grappled with the question.
First Public Discussion On How EU Medtech Regulatory Governance Structure May Evolve
Does the EU need a medtech agency for the first time in its history? Nothing can or should be decided too quickly but five high-profile experts broadly agreed that change is now critical.
First Danish Notified Body Named Under EU's Medical Device Regulation
The EU now has a total of 45 notified bodies under the MDR.